Abstract:Acute graft-versus-host disease (GVHD) is a primary T-cell-mediated complication of allogeneic hematopoietic stem cell transplantation (HSCT), occurring when donor-derived T cells are stimulated by host antigen-presenting cells (APCs), enhanced by proinflammatory cytokines such as interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor (TNF)-alpha. Recent data indicate that besides differences in major histocompatibility and minor histocompatibility antigens, cytokine gene polymorphisms have a predictive value for the complication of GVHD. Patients with a high anti-inflammatory IL-10 production have been demonstrated to be protected from GVHD while patients with high TNF-alpha serum levels were more at risk for GVHD. Pharmacological immunosuppression for GVHD prophylaxis and therapy, including unspecific approaches with corticosteroids or methotrexate (MTX), as well as more specific therapy with cyclosporin A (CsA), tacrolimus (FK506), sirolimus, mycophenolate mofetil (MMF), antithymocyte globulin (ATG), and monoclonal antibodies (MAbs) directed against CD3, CD25, CD52, cytotoxic T-lymphocyte antigen (CTLA)-4, CD40 ligand, or TNF-alpha, have been proven to be effective. Recent data on novel techniques to selectively deplete alloreactive T cells by removal, destruction, or anergy induction while preserving leukemia-specific T-cell clones suggest a clinical benefit from these approaches. Gene-modified T cells that can selectively be depleted and CD4+CD25+ regulatory T cells are under investigation for their ability to modulate alloreactivity after HSCT. With a better understanding of the immunopathogenesis of acute GVHD and the technical improvement of recently described therapeutic approaches, such as removal of naive T cells, selection of Th2 cells, suicide gene transduced T cells, and adoptive transfer of regulatory T cells, the use of alloreactivity as a treatment modality may be expanded to nonhematological disease entities such as solid tumors or autoimmune disorders.

Pathogenesis and Prevention of Transfusion-Associated Graft-versus-Host Disease]

Transfusion-associated Graft-Versus-host-disease: Case Report and Review of Literature

Risk and Prognostic Factors of Transplantation‐associated Thrombotic Microangiopathy in Allogeneic Haematopoietic Stem Cell Transplantation: a Nested Case Control Study

[Graft Failure in Allogeneic Hematopoietic Stem Cell Trans-Plantation].

Evaluation the Risk Factor of Transplantation-Associated Thrombotic Microangiopathy.

Irradiation of Blood Components to Prevent Transfusion-Associated Graft-Versus-host Disease in Immunological Deficient Patients with Hematological Malignances

Impairment of bone marrow endothelial progenitor cells in acute graft-versus-host disease patients after allotransplant.

Transplant Associated Graft versus Host Disease

Acute graft-vs-host disease: pathobiology and management

Diagnosis and treatment of acute graft-versus-host disease after liver transplantation: Report of six cases

[Pathogenesis and Therapeutic Prospects of Chronic Graft-Versus-Host Disease --Review]

PRELIMINARY CHINICAL EXPERIENCE OF LIVER TRANSPLANT-ASSOCIATED GRAFT-VERSUS-HOST DISEASE.

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease

The Risk Factors and Prognosis of Transplant-Associated Thrombotic Microangiopathy Following Acute Graft-Versus-host Disease

Embracing the Age of Artificial Intelligence: Paradigm Shifts, Opportunities, and Challenges in the Treatment of Acute Graft-Versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies

[Analysis of Risk Factors for the Development of Acute Graft-Versus-host Disease in 151 Cases of Allo-Hematopoietic Stem Cell Transplantation].

Diagnosis And Differential Diagnosis Of Hepatic Graft Versus Host Disease (Gvhd)

Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

Status on pathogenesis, diagnosis and treatment of hematopoietic stem cell transplantation associated thrombotic microangiopathy

X‐ray irradiation effectively inactivated lymphocytes in transfusion in vivo monitored by the bioluminescence transfusion‐associated graft‐versus‐host disease model